<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04938635</url>
  </required_header>
  <id_info>
    <org_study_id>VIT-2763-THAL-203</org_study_id>
    <secondary_id>2021-001639-23</secondary_id>
    <nct_id>NCT04938635</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia</brief_title>
  <official_title>A Phase 2b, Double-blind, Randomised, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of VIT-2763 Multiple Doses in Adults With Transfusion-dependent Beta-thalassaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor (International) Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vifor Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy of 3 multiple doses of VIT-2763 as&#xD;
      measured by the reduction in red blood cell (RBC) transfusion burden from Week 13 to Week 24,&#xD;
      to identify the most efficacious and safe dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients giving written informed consent will undergo a 12-week screening period to&#xD;
      determine eligibility for study entry. At Day 1, patients who meet the eligibility&#xD;
      requirements will be randomized in a double-blind manner to 1 of 4 treatment groups: VIT-2763&#xD;
      60 mg (once daily), 60 mg (twice daily), or 120 mg (twice daily) or placebo.&#xD;
&#xD;
      The randomisation will be stratified (balanced allocation across treatment groups) according&#xD;
      to β0/β0 genotype (yes/no).&#xD;
&#xD;
      The duration of the treatment with VIT-2763 or placebo is 24 weeks, after which patients will&#xD;
      undergo a 12-week post-treatment follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving ≥33% reduction of RBC transfusions from baseline and a reduction of ≥2 units assessed consecutively from Week 13 to Week 24 compared to the baseline transfusion</measure>
    <time_frame>Week 13 to Week 24 comparing to Baseline (Day -83 to Day 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in RBC transfusions over Weeks 13 to 24 compared to the baseline RBC transfusion burden derived using the last 12 weeks prior to randomization.</measure>
    <time_frame>Week 13 to Week 24 comparing to Baseline (Day -83 to Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving ≥50% reduction of RBC transfusions and ≥2 units assessed over any consecutive 12-week interval from Week 1 to 24.</measure>
    <time_frame>Any consecutive 12-week interval from Week 1 to Week 24 comparing to Baseline (Day -83 to Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving ≥33% reduction of RBC transfusions and ≥2 units assessed over any consecutive 12-week interval from Week 1 to 24.</measure>
    <time_frame>Any consecutive 12-week interval from Week 1 to Week 24 comparing to Baseline (Day -83 to Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Quality of Life (QoL) total score</measure>
    <time_frame>Week 15 and Week 24 comparing to Baseline (Day 1)</time_frame>
    <description>Transfusion-dependent QoL Questionnaire (TranQuol): a disease-specific, validated, QoL measure developed for thalassemia patients. The adult version includes 36 questions grouped into 5 domains: physical health, emotional health, sexual health, family functioning, and school/career functioning. The total score ranges from 0 (worst) to 100 (best).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Beta-Thalassemia</condition>
  <arm_group>
    <arm_group_label>VIT-2763 60 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VIT-2763 60 mg administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIT-2763 60 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VIT-2763 60 mg administered twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIT-2763 120 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VIT-2763 120 mg administered twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule administered twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIT-2763 60 mg QD</intervention_name>
    <description>Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.</description>
    <arm_group_label>VIT-2763 60 mg QD</arm_group_label>
    <other_name>Vamifeport 60 mg QD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIT-2763 60 mg BID</intervention_name>
    <description>Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.</description>
    <arm_group_label>VIT-2763 60 mg BID</arm_group_label>
    <other_name>Vamifeport 60 mg BID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIT-2763 120 mg BID</intervention_name>
    <description>Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.</description>
    <arm_group_label>VIT-2763 120 mg BID</arm_group_label>
    <other_name>Vamifeport 120 mg BID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight ≥40.0 kg and ≤100 kg at screening&#xD;
&#xD;
          -  Documented diagnosis of beta-thalassemia or Hb E/beta-thalassemia&#xD;
&#xD;
          -  Red blood cell (RBC) transfusion dependence, defined as at least 6 RBC units in the 24&#xD;
             weeks prior to randomization and no transfusion-free period for ≥35 days during that&#xD;
             period&#xD;
&#xD;
          -  Ability to understand the requirements of the study and provide written informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of Hb S/beta-thalassemia, alpha-thalassemia, or delta beta&#xD;
             (δβ)-thalassemia, or hereditary persistence of foetal Hb.&#xD;
&#xD;
          -  History of partial or total splenectomy within 4 months prior to screening.&#xD;
&#xD;
          -  History of myocardial iron overload&#xD;
&#xD;
          -  Chronic liver disease or history of liver cirrhosis&#xD;
&#xD;
          -  Clinically relevant renal disease&#xD;
&#xD;
          -  History or clinically important finding of cardiac disorders&#xD;
&#xD;
          -  History of clinically significant lung disease&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt; Grade 1 according to NCI CTCAE current version)&#xD;
&#xD;
          -  Unable to take and absorb oral medications.&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  History of drug or alcohol abuse within 2 years prior to screening&#xD;
&#xD;
          -  History or concomitant solid tumors and/or hematological malignancies unless resolved&#xD;
             in the ≥5 past years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Richard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vifor (International) Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>VIT-2763-THAL-203 Clinical Study Team</last_name>
    <phone>+41 588 518 000</phone>
    <email>VIT2763THAL203.study@viforpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator site #710</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603-2137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Beta-Thalassemia</keyword>
  <keyword>Transfusion-dependent Thalassemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

